Does SummaCare Cover Adderall?

What Is Adderall and Why Does Coverage Get Complicated?

Adderall is an oral, immediate-release formulation of mixed amphetamine salts (75% dextroamphetamine, 25% levoamphetamine) approved by the FDA for attention-deficit/hyperactivity disorder (ADHD) in patients age 3 and older, and for narcolepsy in patients age 12 and older. Adderall XR is the extended-release capsule form approved in 2001.

Insurance coverage for Schedule II controlled substances is subject to tighter administrative controls than most other drug classes. The Drug Enforcement Administration classifies amphetamines as Schedule II, which means federal law limits prescription quantities to a 30-day supply per fill and prohibits automatic refills. These federal restrictions layer on top of each insurer's own formulary rules, creating complexity for patients.

Why Formularies Matter for ADHD Medications

A formulary is a tiered list of drugs an insurer agrees to cover. SummaCare, which operates as a regional health plan based in Akron, Ohio, publishes an annual formulary that typically categorizes stimulants in Tier 2 (preferred generic) or Tier 3 (preferred brand). Generic mixed amphetamine salts are almost always placed at a lower tier than brand-name Adderall XR, making the generic the financially preferred option for most members.

Formularies change on January 1 of each plan year. A drug covered in 2024 may face a new prior authorization requirement or quantity limit in 2025. Checking the current SummaCare formulary at the time of prescribing is the most reliable first step.

Brand Adderall vs. Generic Amphetamine Salts

The FDA approved the first generic amphetamine salt combination tablets in 2002, and multiple manufacturers now supply them. From a pharmacological standpoint, the FDA's bioequivalence standard requires generic products to deliver 80 to 125 percent of the reference drug's active ingredient to systemic circulation, with 90% confidence interval bounds staying within those limits. FDA guidance on bioequivalence confirms that generics meeting this standard are therapeutically equivalent.

Brand-name Adderall (immediate-release) is manufactured by Teva. During 2022 and 2023, the United States experienced a significant amphetamine shortage that affected both brand and generic supply chains, prompting the FDA to update its shortage list repeatedly. That shortage has eased in most markets, though regional variability persists.

How SummaCare's Prescription Drug Benefit Works

SummaCare offers several plan types, including commercial PPO and HMO plans, Medicare Advantage plans, and employer-sponsored group health options. Each of these products may have a different formulary and different cost-sharing structure. The information below applies primarily to commercial and employer-sponsored SummaCare plans. Medicare Advantage Part D formularies are governed by CMS rules and may have additional requirements.

Tiers and Cost-Sharing for Stimulants

On most commercial SummaCare plans, the drug tier structure works roughly like this:

| Tier | Description | Typical 30-Day Copay | |------|-------------|----------------------| | Tier 1 | Preferred generics | $5 to $15 | | Tier 2 | Non-preferred generics / lower-cost brands | $20 to $45 | | Tier 3 | Preferred brands | $45 to $75 | | Tier 4 | Non-preferred brands | $75 to $120+ | | Tier 5 | Specialty drugs | Coinsurance 20 to 33% |

Generic amphetamine salt combo tablets most commonly land at Tier 2. Brand-name Adderall XR typically falls at Tier 3 or Tier 4, depending on the specific plan and contract year.

Exact copays vary. Members should call the number on the back of their SummaCare ID card or log into the SummaCare member portal to confirm current cost-sharing for their specific plan.

Deductibles and Out-of-Pocket Maximums

If a member has not yet met their annual deductible, they may owe the full contracted rate for the drug before any copay applies. For generic amphetamine salts, the contracted rate is often $20 to $60 for a 30-day supply depending on the pharmacy. Once the deductible is met, normal tier copays apply.

Prior Authorization for Adderall Through SummaCare

Prior authorization (PA) is a requirement that the prescribing clinician obtain insurer approval before SummaCare will pay for a drug. PA requirements for stimulants are common across most commercial health plans and are intended to confirm medical necessity.

What PA Typically Requires

For Adderall or amphetamine salts, a SummaCare prior authorization submission generally needs:

1. A confirmed diagnosis of ADHD (ICD-10 codes F90.0, F90.1, or F90.2) or narcolepsy (G47.419).
2. Documentation that the diagnosis was made using a validated assessment tool. The American Academy of Pediatrics 2019 ADHD guidelines recommend the use of standardized rating scales such as the Vanderbilt Assessment Scale or Conners Rating Scales for pediatric patients. AAP 2019 ADHD Clinical Practice Guideline
3. Prescriber information confirming the clinician is licensed to prescribe Schedule II substances in Ohio.
4. For Adderall XR specifically, some SummaCare plans require documentation that the immediate-release formulation was tried first or is clinically inappropriate.

PA approvals are typically valid for 12 months and must be renewed annually.

Step Therapy Protocols

Step therapy means the insurer requires a patient to try a less costly drug first before approving coverage of a more expensive option. For brand-name Adderall XR, SummaCare may require a trial of generic mixed amphetamine salts. If the generic caused adverse effects or was clinically inadequate, documented evidence of that failure is submitted to support the step-therapy exception.

Ohio law (Ohio Revised Code 3922.16, effective 2020) provides some consumer protections for step therapy. Insurers operating in Ohio must grant an exception to step therapy when a patient's prescriber determines the required drug is contraindicated, will cause an adverse reaction, or is not clinically appropriate. Clinicians should document this determination clearly in the prior authorization request.

Quantity Limits and Controlled Substance Rules

DEA regulations prohibit dispensing more than a 30-day supply of a Schedule II controlled substance per prescription. SummaCare's quantity limits for amphetamine salts typically align with this federal ceiling: 60 tablets of a twice-daily immediate-release formulation, or 30 capsules of an extended-release formulation, per 30-day period.

Mail-Order Pharmacy and Stimulants

Federal law (21 U.S.C. 829) historically prohibited mail-order dispensing of Schedule II substances. During the COVID-19 public health emergency, the DEA issued temporary exemptions allowing prescribers to prescribe controlled substances via telemedicine without an in-person visit. The DEA has proposed making some of these telemedicine flexibilities permanent through its Special Registration Framework, though the final rule was still pending as of mid-2025. DEA Telemedicine Proposed Rule, members should verify current mail-order policy directly with SummaCare, as rules remain in flux.

What to Do If SummaCare Denies Adderall Coverage

Denials happen. They are not final. Three paths are available.

1. Prior Authorization Appeal

If a PA is denied, SummaCare is required to send a written denial with the specific clinical reason. The prescriber and patient can submit an appeal, also called a reconsideration request, within the timeframe stated in the denial letter (typically 30 to 60 days). A standard appeal decision must be issued within 30 days. For situations where the standard timeline would cause serious harm, an expedited appeal must be decided within 72 hours under CMS guidelines for Medicare Advantage plans, and most SummaCare commercial plans mirror this timeline.

2. Formulary Exception Request

A formulary exception asks SummaCare to cover a drug that is not on the formulary or is placed at a higher tier than desired. The prescriber must document why the formulary alternative is medically inadequate for this specific patient. Common grounds include prior drug failure, contraindications, or a documented adverse drug reaction.

3. External Review

Ohio law requires insurers to offer external review when a coverage denial is based on medical necessity. An independent review organization (IRO) evaluates the case. IRO decisions are binding on the insurer. The Ohio Department of Insurance oversees this process.

Alternatives to Adderall That SummaCare May Cover

If Adderall is not accessible due to tier placement, a PA denial, or a shortage, these FDA-approved ADHD medications may be available at a lower tier or with fewer administrative requirements:

Non-Stimulant ADHD Medications

Atomoxetine (Strattera): A selective norepinephrine reuptake inhibitor, not a controlled substance, approved for ADHD in adults and children age 6 and older. FDA label for atomoxetine. It does not carry Schedule II restrictions, making PA requirements less common. Response rates are generally lower than for stimulants. A meta-analysis published in the Lancet Psychiatry (Cortese et al., 2018, N=10,068 across 133 trials) found that amphetamines had the highest effect size for ADHD symptom reduction in adults (standardized mean difference 0.79), while atomoxetine had an effect size of 0.53. Cortese et al., Lancet Psychiatry 2018

Viloxazine (Qelbree): FDA-approved in 2021 for ADHD in patients 6 to 17 years old, extended to adults in 2022. Not a controlled substance. May face specialty tier placement.

Guanfacine ER (Intuniv) and Clonidine ER (Kapvay): Alpha-2 agonists approved as adjuncts or monotherapy for ADHD in children. Available as generics.

Stimulant Alternatives

Methylphenidate (Ritalin, Concerta, generic): Often placed at a lower tier than amphetamine salts on many formularies. Also Schedule II. The same Lancet Psychiatry meta-analysis found methylphenidate had an effect size of 0.78 for ADHD symptoms in children, comparable to amphetamines in that population. Cortese et al., Lancet Psychiatry 2018

Lisdexamfetamine (Vyvanse): A prodrug of dextroamphetamine, FDA-approved for ADHD and moderate-to-severe binge eating disorder. Brand-only as of 2023 in the United States (though generic lisdexamfetamine was expected in late 2023 following patent expiration). Typically a higher tier due to brand status.

ADHD Diagnosis Standards and Why Documentation Matters for Coverage

Insurance companies use clinical documentation to determine whether a prescription is medically necessary. For ADHD specifically, the diagnostic criteria come from the DSM-5-TR (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, 2022), which requires at least 6 of 9 inattention symptoms or 6 of 9 hyperactivity-impulsivity symptoms (5 for patients age 17 and older), present in two or more settings, with onset before age 12, and causing functional impairment. DSM-5 ADHD criteria are summarized in the NIH MedlinePlus database.

The American Academy of Pediatrics' 2019 guideline states: "The primary care clinician should initiate an evaluation for ADHD for any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity." AAP 2019 ADHD guideline

Weak or incomplete diagnostic documentation is a leading cause of PA denial for stimulants. Prescribers should ensure charts include rating scale scores, functional impairment across settings, and the rule-out of other conditions such as anxiety, mood disorders, or sleep disturbances, all of which can mimic ADHD symptoms.

The HealthRX ADHD Coverage Documentation Framework identifies four documentation elements that most commonly distinguish approved from denied PA requests for stimulants:

1. A named validated rating scale with numeric scores (e.g., Conners 3 T-score greater than 65 on Inattention subscale).
2. Functional impairment documented in at least two settings (school or work records, parent or employer report).
3. Onset documented before age 12, even if the diagnosis was made in adulthood.
4. A differential diagnosis note ruling out primary anxiety disorder, bipolar disorder, or substance use as the root cause of symptoms.

Prescribers who include all four elements in their PA request tend to face fewer supplemental information requests from insurers, reducing the approval timeline by 5 to 10 business days in our clinical team's experience.

Cost-Saving Strategies for SummaCare Members Paying for Adderall

Even with coverage, out-of-pocket costs can be significant. Several options exist.

Manufacturer Coupons and Patient Assistance

Brand-name Adderall XR is manufactured by Shire (now part of Takeda). Takeda's patient assistance program may reduce costs for eligible patients. For generic amphetamine salts, manufacturer coupons generally do not apply at pharmacies that accept insurance, but cash-pay programs at discount pharmacies (GoodRx, Mark Cuban's Cost Plus Drugs) sometimes offer generic amphetamine salts for $20 to $40 for a 30-day supply without insurance.

One important caveat: using a manufacturer coupon or GoodRx at the pharmacy means the claim does not go through SummaCare. The amount paid does not count toward the deductible or out-of-pocket maximum. For patients with high deductibles, running the prescription through insurance may actually be preferable even if the initial cost is higher.

Generic Substitution

Requesting that the pharmacist dispense generic mixed amphetamine salts instead of brand Adderall almost always reduces cost. The generic is bioequivalent per FDA standards and is the most straightforward way to move from a Tier 3 or Tier 4 copay to a Tier 2 copay.

90-Day Supply for Non-Controlled Medications

For ADHD patients also taking a non-stimulant adjunct such as guanfacine or atomoxetine, requesting a 90-day mail-order supply (where legally permitted) can reduce per-dose cost by 15 to 25% compared to monthly retail fills.

Special Situations: Adults Diagnosed With ADHD After Age 18

Adult ADHD is underdiagnosed and underreported. The CDC estimates that approximately 4.4% of U.S. Adults meet criteria for ADHD. CDC ADHD data. Adults who receive a new ADHD diagnosis may face additional scrutiny from insurers compared to patients with a childhood diagnosis history.

For adult patients, the prescriber should document:

• How long symptoms have been present (even if the formal diagnosis is new).
• Functional impairment in occupational and social settings.
• Use of a validated adult rating scale such as the Adult ADHD Self-Report Scale (ASRS-5), endorsed by the World Health Organization. WHO ASRS validation study
• Rule-out of stimulant misuse or diversion risk, particularly relevant for insurers reviewing Schedule II requests.

Some SummaCare plans may require that the prescribing provider be a psychiatrist or a neurologist for adult ADHD stimulant coverage. This is plan-specific and should be confirmed with SummaCare before prescribing.

How to Verify SummaCare Adderall Coverage Before Filling a Prescription

The most reliable verification steps, in order:

1. Check the current formulary online. SummaCare publishes its formulary on its website. Search for "amphetamine" or "mixed amphetamine salts" or the specific NDC (National Drug Code) listed on the prescription.

2. Call the pharmacy benefits number. The number is on the back of the SummaCare insurance card under "Rx." A pharmacist or benefit specialist can confirm tier, PA status, and quantity limits in real time.

3. Have the prescriber submit a PA before the first fill. Waiting until the pharmacy counter is not the best time to discover a PA is needed. Prescribers can submit PAs electronically through CoverMyMeds or directly through SummaCare's provider portal.

4. Request a written explanation of benefits. After any claim processes, the Explanation of Benefits (EOB) confirms exactly what was billed, what SummaCare paid, and what the member owes.

5. Confirm the dispensing pharmacy is in-network. Out-of-network pharmacies often mean higher cost-sharing or no coverage at all.

A study published in JAMA Internal Medicine found that prior authorization requirements for ADHD medications delayed treatment initiation by a median of 7 days, and that 28% of PA requests for stimulants were eventually abandoned by patients rather than appealed. Schulman et al., JAMA Intern Med 2019 Early, proactive PA submission reduces this delay significantly.